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Abstract
Introduction: Inflammatory breast cancer (IBC) is an aggressive, metastatic and highly angiogenic form of locally
advanced breast cancer with a relatively poor three-year survival rate. Breast cancer invasion has been linked to
proteolytic activity at the tumor cell surface. Here we explored a role for active cathepsin B on the cell surface in
the invasiveness of IBC.
Methods: We examined expression of the cysteine protease cathepsin B and the serine protease urokinase
plasminogen activator (uPA), its receptor uPAR and caveolin-1 in two IBC cell lines: SUM149 and SUM190. We
utilized a live cell proteolysis assay to localize in real time the degradation of type IV collagen by IBC cells. IBC
patient biopsies were examined for expression of cathepsin B and caveolin-1.
Results: Both cell lines expressed comparable levels of cathepsin B and uPA. In contrast, levels of caveolin-1 and
uPAR were greater in SUM149 cells. We observed that uPA, uPAR and enzymatically active cathepsin B were
colocalized in caveolae fractions isolated from SUM149 cells. Using a live-cell proteolysis assay, we demonstrated
that both IBC cell lines degrade type IV collagen. The SUM149 cells exhibit predominantly pericellular proteolysis,
consistent with localization of proteolytic pathway constitutents to caveolar membrane microdomains. A functional
role for cathepsin B was confirmed by the ability of CA074, a cell impermeable and highly selective cathepsin B
inhibitor, to significantly reduce pericellular proteolysis and invasion by SUM149 cells. A statistically significant co-
expression of cathepsin B and caveolin-1 was found in IBC patient biopsies, thus validating our in vitro data.
Conclusion: Our study is the first to show that the proteolytic activity of cathepsin B and its co-expression with
caveolin-1 contributes to the aggressiveness of IBC.
Introduction
Inflammatory breast cancer (IBC) is the most lethal type
of breast cancer with a three-year survival rate of 42%
as compared with 85% for non-IBC [1]. In 2010, an
international panel of leading experts recommended the
clinical consensus for a minimal standard diagnosis of
IBC include erythema occupying at least one-third of
the breast, hardening and retraction of the nipple, dim-
pling (peau d’orange) of the skin, and no response to
antibiotic treatment [2]. These clinical characteristics
are accompanied by extensive dermal lymphovascular
invasion in which tumor emboli are present within der-
mal lymphatics [3].
Proteases such as the cysteine protease cathepsin B
have been implicated in the initiation, promotion and
dissemination of cancers including IBC [4-6]. In IBC,
high levels of cathepsin B are found to correlate with
increases in numbers of metastatic lymph nodes [7]. In
tumor cells, cathepsin B redistributes into exocytic vesi-
cles at the cell periphery leading to its secretion and
association with the tumor cell surface by binding to the
light chain of the annexin II heterotetramer [8,9]. More
specifically, we have shown that in colon cancer cells
cathepsin B localizes in caveolae [10], a membrane
microdomain in which the annexin II heterotetramer is
also localized [11]. Downregulation of caveolin-1, the
structural protein of caveolae, reduces the cell surface
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type IV collagen and invasion by the colon cancer cells,
consistent with a functional role for caveolae-associated
cathepsin B in invasion [12].
Caveolin-1 was initially hypothesized to be a tumor
suppressor in breast cancer [13]. More recent data sug-
gest that high expression of caveolin-1 is a characteristic
of triple-negative and other basal-like breast cancers
[14], including IBC of a basal phenotype. Indeed, caveo-
lin-1 is highly expressed in both IBC cells and tissues
[7,15,16]. We previously hypothesized that the high
levels of caveolin-1 expression in bladder, colon, esopha-
geal and prostate cancers promote cell surface proteoly-
tic events that lead to extracellular matrix (ECM)
degradation and tumor invasion [17]. For example, pro-
teases of the plasminogen cascade, specifically pro-uro-
kinase plasminogen activator (pro-uPA) and its receptor
uPAR have been localized to caveolae [12,18]. These
findings may be of functional significance as cathepsin B
is capable of processing the zymogen pro-uPA to its
active derivative uPA [19] and is found upstream of
plasminogen in a proteolytic pathway on the surface of
a number of cell lines [20-22]. Moreover, uPAR com-
plexes with caveolin-1 via b1-integrin, an association
that has been shown to mediate uPAR-dependent adhe-
sion and b1-integrin-induced signal transduction
[23,24]. This suggests that caveolae may serve as sites
on the cell surface linking proteolytic and signaling
pathways that are involved in tumor invasion.
We hypothesize that participation of cathepsin B in
IBC invasion is facilitated by its colocalization at the cell
surface with members of the plasminogen cascade and
the expression of caveolin-1. Here we demonstrate that
cathepsin B as well as uPA and uPAR are associated
with caveolar fractions in IBC cells and that cathepsin B
is active within these fractions. We confirmed that
cathepsin B and caveolin-1 are coexpressed in tissues
from IBC patients.
Materials and methods
Cell lines
SUM149 and SUM190 human IBC cell lines [25] (a kind
gift from Dr. Stephen Ethier, Wayne State University,
Detroit, MI, USA) were cultured in Hams F-12 media
(Mediatech, Manassas, VA, USA) containing 5 μg/ml
insulin, 1 μg/ml hydrocortisone, antibiotics (penicillin/
streptomycin), and 5% (SUM149) and 2% (SUM190)
f e t a lb o v i n es e r u m( H y C l o n e ,L o g a n ,U T ,U S A ) .M e d i a
for SUM190 cells were further supplemented with 5
mM ethanolamine, 10 mM HEPES, 5 μg/ml transferrin,
6.6 ng/ml 3,3’,5-triiodo-L-thyronine sodium salt, 8.7 ng/
ml sodium selenite, and 1 mg/ml bovine serum albumin.
All cells were maintained in 5% CO2/humidified atmo-
sphere at 37°C. Unless otherwise stated all tissue culture
reagents were from Sigma Aldrich (St. Louis, MO,
USA).
Preparation of cell lysates and conditioned media
IBC cells were grown on plastic to 70% confluency and
then serum-starved overnight. Conditioned media were
collected and centrifuged at 100 × g at 4°C to remove
whole cells, and then re-centrifuged at 800 × g at 4°C to
remove cell debris. All conditioned media samples were
concentrated to equal volumes in Ultrafree-0.5 PBGC
Centrifugal Filter Units with 5 kDa molecular weight
cut off Biomax Membranes (Millipore, Billerica, MA,
USA). Cells were harvested in lysis buffer (10 mM Tris,
pH 7.5, 150 mM NaCl, 1% Triton X-100, 60 mM octyl-
glucoside) and then passed 10 times through a syringe
with a 20-gauge needle and centrifuged for five minutes
at 10,000 × g at 4°C. Supernatants were recovered and
protein concentrations were quantified using micro-
BCA reagents according to the manufacturer’si n s t r u c -
tions (Pierce, Rockford, IL, USA).
Preparation of 3D reconstituted basement membrane
overlay cultures
Sixty mm dishes were coated with 300 μlo fr e c o n s t i -
tuted basement membrane (rBM; Cultrex, Trevigen,
Gaithersburg, MD, USA) and allowed to solidify for 15
minutes at 37°C. Cells (1 × 10
6)w e r es e e d e do nt o po f
solidified rBM and grown in complete media containing
2% rBM. Within 24 hours, cells formed 3D spheroid
structures.
Isolation of caveolae-enriched fractions
Non-detergent and detergent-based protocols were used
to prepare caveolae-enriched membrane fractions of IBC
cells [26]. In the non-detergent based method, cells
grown as a two-dimensional (2D) monolayer on plastic (4
× 100 mm dishes) and three-dimensional (3D) on rBM (4
× 60 mm dish) for two and five days, respectively, were
washed with PBS, collected into 500 mM sodium carbo-
nate buffer, pH 11.0, homogenized in a Dounce homoge-
nizer on ice and sonicated three times for 10 seconds
each. A discontinuous sucrose gradient was prepared as
previously detailed [26]. Briefly, the cell homogenate was
mixed thoroughly with an equal volume of 90% (w/v)
sucrose, then overlaid with 35% (w/v) sucrose and 5% (w/
v) sucrose and subsequently ultracentrifuged (185,000 ×
g) for 19 hours at 4°C. Fractions of 1 mL were collected
and equal-volume aliquots of fractions 3-11 were ana-
lyzed by SDS-PAGE and immunoblotting.
A successive detergent-based method of cell fractiona-
tion was also employed to separate Triton X-100-soluble
(TS) and Triton X-100-insoluble (TI) membrane frac-
tions [27]. 3D cultures were prepared and grown, as
described above, for two days and thereafter washed
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taining 1% Triton X-100 for 20 minutes on ice, collected
and centrifuged at 14,000 × g for 10 minutes at 4°C. The
supernatant (TS fraction) was collected and the pellet
was resuspended in 300 μl of lysis buffer containing 1%
Triton X-100 plus 60 mM octylglucoside, incubated on
ice for 20 minutes, passed through a syringe with a
21.5-gauge needle and centrifuged at 14,000 × g for 10
minutes at 4°C. The supernatant (TI fraction) was
recovered. Equal-volume aliquots of each fraction were
analyzed by SDS-PAGE and immunoblotting.
SDS-PAGE and immunoblotting
Cell lysates and conditioned media samples were equally
loaded on the basis of the protein concentration of the
respective cell lysates, separated by SDS-PAGE (10 or
12%) under either reducing or non-reducing conditions,
transferred to nitrocellulose membranes and immuno-
blotted with primary antibodies against human cathepsin
B (1:4000; [28]), b1-integrin (1:3000; a kind gift from Dr.
Kenneth Yamada, National Institute of Dental and Cranio-
facial Research, National Institutes of Health, Bethesda,
MD, USA), uPA (1:2000; Abcam, Cambridge, MA, USA),
uPAR (1:2000; Abcam, Cambridge, MA, USA), caveolin-1
(1:4000; BD Biosciences, Bedford, MA, USA), or b-tubulin
(1:1500; prepared from hybridoma E7 cells, Developmental
Studies Hybridoma Bank, National Institute of Child
Health and Human Development, University of Iowa,
Iowa City, IA, USA) and secondary antibodies conjugated
with horseradish peroxidase (HRP; 1:10,000; Pierce) in
TBS buffer (20 mM Tris, pH 7.5, 0.5 M NaCl) containing
0.5% Tween 20 and 5% (w/v) non-fat dry milk. After wash-
ing, bound antibodies were detected by enhanced chemilu-
minescence according to the manufacturer’s instructions
(PerkinElmer, Waltham, MA, USA).
Cathepsin B activity assay
Cathepsin B activity was measured using the synthetic
fluorometric substrate Z-Arg-Arg-NHMec as previously
described [10]. Briefly, equal-volume aliquots of TS and
TI fractions were incubated with activator buffer for 15
minutes at 37°C. Following this activation step, 150 μM
Z-Arg-Arg-NHMec (pH 6.0) was added to the assay
buffer and fluorescence was measured in triplicate, at
one-minute intervals for 30 minutes, at an excitation of
360 nm and an emission of 465 nm. Data are repre-
sented as relative fluorescent units and presented as
mean ± standard deviation (SD) of three independent
experiments. Statistical significance was determined by a
two-tailed t-test with assumed equal variance.
Live-cell proteolysis assay
Proteolytic cleavage of DQ-collagen IV substrate (Invi-
trogen, Carlsbad, CA, USA) by live IBC cells was imaged
in real time and quantified as previously described
[29,30]. Briefly, IBC cells (2.5 × 10
4) were seeded on
round glass coverslips coated with rBM containing 25
μg/ml DQ-collagen IV substrate and incubated at 37°C
for 40 minutes to allow for cell attachment before add-
ing complete media containing 2% rBM. Following 24 to
48 hours of incubation at 37°C and 5% CO2, live cells
were imaged (37°C and 5% CO2) with a Zeiss LSM 510
META NLO confocal microscope using a 40× Plan neo-
fluar (N.A., 0.7) objective. DQ-collagen IV cleavage pro-
ducts were observed as green fluorescence. Where
specified, the assay was performed in the presence of 10
μM CA074 (Peptides International, Louisville, KY,
USA). Statistical significance was determined by a two-
tailed t-test with assumed equal variance.
Invasion assay
Cell culture inserts (8.0 μm transparent PET membranes
(BD Biosciences, Franklin Lakes, NJ, USA)), were coated
with 2 mg/ml rBM and incubated in a 24-well plate at
room temperature to permit rBM solidification. SUM149
cells (5.0 × 10
4) in serum-free media were seeded onto
the rBM-coated inserts and incubated for 24 hours at 37°
C in the presence of dimethyl sulfoxide (DMSO, vehicle
control) or 10 μM CA074. The stimulant for invasion
was complete media. Cells that had not invaded were
removed with a cotton swab. Cells that had invaded were
fixed with 3.7% formaldehyde (Polysciences, Inc., War-
rington, PA, USA), stained with 4’,6-diamidino-2-pheny-
lindole (Invitrogen, Carlsbad, CA, USA) and imaged at
20× magnification with a Zeiss Axiophot conventional
epifluorescent microscope. Ten random microscopic
fields per filter were analyzed. The number of cells that
invaded was assessed by counting nuclei with Meta-
Morph™ image analysis software (Molecular Devices,
Sunnyvile, CA, USA). Statistical significance was deter-
mined by a two-tailed t-test with assumed equal variance.
Immunocytochemical staining
Intracellular co-staining was performed at room tem-
perature on 2D (permeabilized with 0.1% saponin) and
3D cultures (permeabilized with 0.2% Triton X-100).
The cultures were incubated with the following primary
antibodies diluted in 0.2% Triton X-100/PBS: rabbit
anti-caveolin-1 (1:50), mouse anti-uPA (1:25), and
mouse anti-uPAR (1:12.5). Secondary antibodies (donkey
anti-rabbit Alexa Fluor 488 and donkey anti-mouse
Alexa Fluor 555 (Invitrogen, Carlsbad, CA, USA)) were
diluted (1:5000) in 0.2% Triton X-100/PBS plus 5% nor-
mal donkey serum. All immunocytochemical staining
was imaged on a Zeiss LSM 510 META NLO confocal
microscope using either a 100× oil Plan neofluar (N.A.,
1.3) objective (2D cultures) or 40X Plan apofluar (N.A.,
0.7) objective (3D cultures).
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Institutional review board approval from Ain Shams
University ethics committee and the National Cancer
Institute, Cairo University, along with patient consent
forms, were obtained for the purpose of patient enroll-
ment in this study. Inclusion criteria for patients and
collection of tissue samples were as previously described
[7]. Pre-treated formalin fixed paraffin embedded IBC (n
= 23) and non-IBC (n = 27) patient tissue samples were
subjected to immunohistochemical (IHC) analysis [7].
Briefly, tissue sections were incubated for one hour at
room temperature with either monoclonal anti-caveolin-
1 (1:150) or polyclonal anti-cathepsin B (1:500) primary
antibodies. A second incubation was performed with
HRP rabbit/mouse (EnVision + Dual Link System-HRP
(DAB +)) for 45 minutes. Nuclei were counterstained
with hematoxylin, sections were mounted with Per-
mount
® and imaged. P values for the relation between
cathepsin B expressing breast carcinoma cells, of both
IBC and non-IBC, and caveolin-1 protein expression
were assessed with a chi-square test.
Results
Cathepsin B and uPA expression and secretion are similar
in SUM149 and SUM190 cells
Cathepsin B has been linked to both pericellular and intra-
cellular proteolysis in breast cancer cells [31]. Here we
examined two IBC cell lines, SUM149 and SUM190, and
found that the two cell lines express comparable levels in
the cell lysates of the mature active forms of cathepsin B
(single chain (31 kDa) and double chain (25/26 kDa heavy
chain + 5 kDa light chain)) and secrete comparable levels
of the inactive precursor form, procathepsin B (43 kDa)
(Figure 1a). A 38 kDa intermediate form of the enzyme
was present only in lysates of the SUM149 cells and
mature double chain cathepsin B was secreted only from
SUM190 cells (Figure 1a); these differences between the
two cell lines are likely to be due to variations in the
Figure 1 Profile of cathepsin B, uPA, uPAR, b1-integrin and caveolin-1 expression in SUM149 and SUM190 cells. Expression of
intracellular proteins was analyzed in duplicate samples of cell lysates, whereas expression of secreted proteins was analyzed in duplicate
samples of conditioned media. Lysates and conditioned media of 2D cultures of SUM149 and SUM190 cells were equally loaded based on the
protein concentration of the respective cell lysate and resolved by 10% SDS-PAGE. Proteins were transferred to a nitrocellulose membrane and
immunoblotted with (a) an anti-cathepsin B (cat B) polyclonal antibody (bands represent proform (43 kDa), intermediate (38 kDa), single chain
mature (31 kDa), and heavy chain (25/26 kDa) of double chain mature cathepsin B); (b) an anti-uPA antibody; (c) anti-uPAR, anti-b1-integrin, anti-
caveolin-1 (cav-1) antibodies and (d) anti-b-tubulin monoclonal antibody with the concentration of a-tubulin in the cell lysate serving as a
loading control for both cell lysates and their respective conditioned media. uPA, urokinase-type plasminogen activator; uPAR, urokinase
receptor.
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mature forms, as we have observed in a variety of human
tumor tissues [28]. We also compared the expression of
uPA in both cell lines because cathepsin B activates both
soluble and cell surface bound pro-uPA [19-22]. Both IBC
cell lines expressed similar levels of intracellular pro-uPA;
however, secretion of pro-uPA was slightly higher from
t h eS U M 1 4 9c e l ll i n e( F i g u r e1 b ) .
uPAR, caveolin-1 and b1-integrin expression is higher in
SUM149 than in SUM190 cells
The cell surface receptor for uPA is uPAR [32,33], a
GPI-anchored membrane glycoprotein that has been
localized to caveolae in a wide variety of cells [12,23,24].
We found that SUM149 cells expressed more receptor
than did SUM190 cells (Figure 1c). Caveolin-1 and b1-
integrin form a trimeric complex with uPAR within
caveolae [24], a complex that mediates cell adhesion and
migration. Therefore, we also compared expression of
caveolin-1 and b1-integrin in the two cell lines. There
was a striking dissimilarity in levels of the two proteins
(Figure 1c), paralleling the difference in expression of
uPAR. The differences observed in expression of cav-1,
uPAR, and b1-integrin, which are involved in localiza-
tion and activation of uPA and cathepsin B at the cell
surface, suggest that cell surface or pericellular proteoly-
sis may also differ between the two cell lines.
SUM149 and SUM190 cells exhibit different patterns of
proteolysis of type IV collagen
We used a functional live-cell proteolysis assay to assess
in real-time degradation of DQ-collagen IV by SUM149
and SUM190 cells. DQ-collagen IV cleavage products
(green fluorescence) were present in cultures of both
cell lines; however, there were distinct differences in
localization of cleavage products (Figure 2) [see Addi-
tional files 1 and 2]. Cleavage products were predomi-
nantly pericellular in the SUM149 cell line indicating
degradation by extracellular proteases at the cell surface.
In contrast, in the SUM190 cell line a distinct punctate
fluorescence pattern was present intracellularly, suggest-
ing that the cleavage products were in intracellular vesi-
cles. This may reflect proteolysis either intracellularly in
the vesicles or extracellularly with degradation fragments
taken up into the vesicles by endocytosis.
uPA, uPAR and b1-integrin colocalize in caveolae-
enriched fractions of SUM149 cells
As levels of expression of caveolin-1, uPAR, and b1-integ-
rin were high in SUM149 cells and we have previously
shown that uPA, uPAR, and b1-integrin colocalize in
caveolar fractions of colorectal carcinoma cells [12], we
isolated caveolae-enriched fractions from SUM149 cells.
We used a non-detergent-based method that employs a
sodium carbonate buffer for cell lysis followed by subcellu-
lar fractionation in a sucrose gradient [26]. Analysis of
caveolae-enriched fractions (i.e., fractions in which caveo-
lin-1 was primarily distributed) revealed that uPA, its
receptor uPAR and b1-integrin were all present in these
fractions (Figures 3a and 3b). This was observed for
SUM149 cells grown either as 2D or 3D cultures. For cell
fractionation studies, sufficient starting material is more
readily obtained from 2D cultures. We prefer, however, to
analyze 3D cultures because they more closely resemble
the in vivo phenotype [34] and have been shown to be pre-
dictive of drug responses in vivo [35]. In agreement with
our fractionation studies, immunostaining of 2D (Figure
3c) and 3D (Figure 3d) cultures of SUM149 cells showed
that uPA and uPAR colocalized with caveolin-1, consistent
with a role for caveolin-1 in the distribution of these pro-
teins to the cell surface.
Active cathepsin B localizes to caveolae of SUM149 cells
We have previously shown, using both detergent and
non-detergent methods, that cathepsin B localizes to
caveolae-enriched fractions of colon carcinoma and
endothelial cells [10,12,26]. Cathepsin B activity is
destroyed in the non-detergent-based method as the cells
are lysed in sodium carbonate buffer at pH 11. Therefore,
to assess localization of cathepsin B to caveolae-enriched
fractions of SUM149 3D cultures, we utilized a deter-
gent-based method that separates TS from TI membrane
components. As caveolae are insoluble in 1% Triton X-
100, the TI fraction contains caveolae and associated pro-
teins and the TS fraction contains proteins from cellular
components that are solubilized by the detergent. As
expected more caveolin-1 was observed in the TI fraction
than the TS fraction (Figure 4a). Mature forms of cathe-
psin B were present in the TI fractions (Figure 4a). Sub-
stantially higher levels of mature cathepsin B were
present in the TS fractions containing lysosomes, the
predominant localization of cathepsin B, which is a lyso-
somal enzyme. Cathepsin B activity was observed in both
caveolar and lysosomal fractions (Figure 4b), at levels
comparable with the levels of mature cathepsin B
detected by immunoblotting (Figure 4a). The enzymatic
activity in the isolated caveolar and lysosomal fractions
was completely abrogated by CA074, a highly selective
inhibitor for cathepsin B [36]. The presence of cathepsin
B activity in the TI fractions would be consistent with a
functional role for cathepsin B at the cell surface.
Inhibition of cathepsin B reduces type IV collagen
degradation and invasion by IBC cells
Our live-cell proteolysis assays indicated that SUM149
cells degrade DQ-collagen IV pericellularly and our frac-
tionation and enzymatic assays indicated that active cathe-
psin B is associated with caveolae of these cells. Therefore,
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SUM190 cells were seeded onto glass-coverslips coated with reconstituted basement membrane containing DQ-collagen IV. Following overnight
incubation at 37°C, cells and DQ-collagen IV cleavage products (green) were imaged using confocal microscopy (see Materials and Methods). 3D
structures of live SUM149 and SUM190 cells degraded DQ-collagen IV pericellularly (arrowhead) and predominantly intracellularly (arrow),
respectively. Confocal Z stack images were reconstructed in 3D [see Additional files 1 and 2] utilizing Volocity™ software (PerkinElmer, Waltham,
MA, USA). Representative merged images of DIC and green channels of the equatorial plane (middle) and planes equidistant, 20 μm, from the
equatorial plane (top and bottom) are also shown. Bar, 20 μm.
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pericellular degradation of DQ-collagen IV. For these cell-
based assays, we used CA074, which is cell-impermeant
and thus would only reduce cathepsin B activity outside
the SUM149 cells. We used our previously established
methods to quantify degradation of DQ-collagen IV on a
per cell basis throughout the entire volume of SUM149
3D cultures [29]. We demonstrated that CA074 signifi-
cantly attenuated degradation of DQ-collagen IV (Figure
5) [see Additional files 3 and 4) and invasion (Figure 6),
suggesting that cathepsin B contributes to pericellular
degradation and invasion by SUM149 cells.
Cathepsin B and caveolin-1 are co-expressed in IBC
tissues in vivo
To demonstrate that there is an association between
cathepsin B and caveolin-1 in vivo,w ei m m u n o s t a i n e d
paraffin-embedded tissue samples from IBC and non-
IBC patients for cathepsin B and caveolin-1. IBC
patients in this study ranged in age from 29 to 60 years
(mean ± SD = 41 ± 8); non-IBC patients ranged in age
from 33 to 67 years (mean ± SD = 50 ± 9). Tumor
grade analysis revealed that 65% and 78% of the IBC
and non-IBC samples, respectively, were grade I or II
and 35% and 22% of the IBC and non-IBC samples,
respectively, were grade III. For further clinical and
pathological characterization of the IBC and non-IBC
samples, see [7]. In the IBC tissues, we observed strong
expression of cathepsin B in tumor cells and in tumor
emboli within dermal lymphatics and moderate expres-
sion in stromal cells (Figures 7a and 7b). There was het-
erogeneous staining for caveolin-1 in tumor emboli
(Figure 7c). Endothelial cells of dermal lymphatics con-
taining tumor emboli that stained strongly for caveolin-
1, consistent with the known high levels of caveolae in
endothelial cells [37]. Furthermore, there was a differ-
ence between IBC and non-IBC carcinoma cells in
regard to co-expression of cathepsin B and caveolin-1.
Figure 3 Localization of uPA, uPAR and b1-integrin to caveolae-enriched fractions of SUM149 cells. Isolation of caveolae from SUM149
cells grown in (a) 2D or in (b) 3D culture was performed using a non-detergent method as described in Materials and Methods. Equal-volume
aliquots of fractions 3-11 were analyzed by SDS-PAGE and immunoblotted with antibodies against uPA, uPAR, b1-integrin, or caveolin-1. Merged
DIC and fluorescent images are representative images of SUM149 (c) 2D or (d) 3D cultures immunostained for caveolin-1 (green) and uPA (red)
or uPAR (red). Colocalization of the two proteins appears yellow (arrows). Confocal microscopy was performed as described in Materials and
Methods. Bar, 10 μm for 2D cultures; 20 μm for 3D cultures. uPA, urokinase-type plasminogen activator; uPAR, urokinase receptor.
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+ or +++), 70% also expressed caveolin-1 (score of ++
or +++), whereas only 19% of non-IBC tumor cells
showed this co-expression (P = 0.001) [see Additional
file 5].
Discussion
IBC is a rare but highly aggressive form of breast cancer
with symptoms that develop rapidly (i.e., weeks or
months) after initial diagnosis [38]. Current IBC-specific
treatments are very limited and development of new
therapeutics is needed, specifically therapies against
pathways that mediate the aggressive IBC phenotype.
IBC is, however, not amenable to laboratory investiga-
tions as there are only two commercially available IBC
cell lines (SUM149 and SUM190) for in vitro investiga-
tions and one human xenograft model (MARY-X)
[25,39]. Our approach in this study was to investigate
which proteases expressed by SUM149 and SUM190
IBC cells are associated with caveolin-1, which is highly
expressed in IBC in vivo [7,16], participate in ECM
degradation and invasion and confirm the presence of
these proteases in IBC patient samples. Our findings
implicate cathepsin B as one contributor to the aggres-
sive IBC phenotype.
Cathepsin B had previously been shown to activate
p r o - u P A ,as e r i n ep r o t e a s ea n dm e m b e ro ft h ep l a s m i -
nogen cascade involved in ECM degradation, matrix
metalloproteinase (MMP) activation, and tumor cell
invasion [19]. In SUM149 cells, uPA and its receptor
uPAR colocalize with active cathepsin B in caveolae.
The presence of active cathepsin B in caveolae of IBC
cells suggests a potential role for this enzyme in pericel-
lular proteolysis as was previously shown in colon carci-
noma cells. Downregulation of caveolin-1 in the colon
carcinoma cells decreases cathepsin B localization to
caveolae in parallel with decreases in ECM degradation
and cell invasion [12]. In the SUM149 cells in this
study, which co-express cathepsin B and caveolin-1, we
determined that degradation of type IV collagen was
predominantly pericellular and that a cell impermeant
cathepsin B inhibitor reduced their degradation of type
IV collagen and invasion. Although significant, the lack
of complete inhibition suggests that cathepsin B was
only one of several proteases in the SUM149 cells that
degrade type IV collagen and mediate invasion. Rao and
colleagues have demonstrated that downregulation of
cathepsin B and MMP9 more effectively reduces inva-
sion of prostate tumor cells in vitro and tumor growth
in vivo than downregulation of either cathepsin B or
MMP9 [40]. On the other hand, downregulation of
cathepsin B and uPAR more effectively reduces invasion
of human glioma cells in vitro and in vivo in an intra-
cranial xenograft model than downregulation of either
cathepsin B or uPAR [41]. The above studies indicate
that proteases can compensate for one another. There is
in addition functional redundancy, including among
cysteine cathepsins [6,42]. A striking example is the
redistribution of active cathepsin × to the surface of
mammary tumor cells isolated from mice deficient in
cathepsin B that had been crossed with mice predis-
posed to develop mammary cancer, in this case MMTV-
PyMT transgenic female mice. Moreover, cathepsin ×
neutralizing antibodies reduced invasion of the cathepsin
Figure 4 Active cathepsin B is localized to caveolae-enriched fractions of SUM149 3D cultures. Caveolae from SUM149 3D cultures were
isolated by a detergent-based method, as described in Materials and Methods, that separates Triton X-100-soluble (TS; non-caveolae) from Triton
X-100-insoluble (TI; caveolae) cellular fractions. (a) Equal-volume aliquots of each fraction were analyzed by SDS-PAGE and immunoblotted with
antibodies against cathepsin B or caveolin-1. (b) TS and TI fractions were assayed for enzymatic activity against the synthetic cathepsin B
substrate Z-Arg-Arg-NHMec. Cathepsin B activity in both TS and TI fractions was inhibited by 10 μM CA074; *, P < 0.01.
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Page 8 of 14Figure 5 Inhibition of cathepsin B activity reduces degradation of DQ-collagen IV by SUM149 3D cultures. SUM149 cells were grown as
3D reconstituted basement membrane overlay cultures containing DQ-collagen IV in the presence of either DMSO (vehicle control) or 10 μM
CA074. Confocal Z stack images were captured and used to generate 3D reconstructions (see legend for Figure 2 for detail) [see Additional files
3 and 4]. (a) Representative 3D reconstructions of DQ-collagen IV degradation products (green), SUM149 nuclei (stained with Hoechst 33342,
blue) and corresponding DIC images (insets). (b) Corresponding intensity map (red being most intense and blue least intense) of DQ-collagen IV
degradation products. Magnification, 40×. (c) Quantification of proteolysis in the entire volume of 3D structures measured as the average
integrated intensity of fluorescence per cell and expressed as percent control. Results from three independent experiments are presented as
mean ± standard deviation; *, P < 0.02.
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Page 9 of 14B-deficient mammary tumor cells, a result that is consis-
tent with cathepsin × compensating for the absence of
cathepsin B [43].
The studies above illustrate that in vitro assays such as
invasion and ECM degradation assays are meaningful
surrogates for in vivo tumor endpoints. In a recent colla-
borative study (N Withana, BF Sloane and BS Parker,
unpublished observations), we demonstrated that either
knockdown or inhibition of cathepsin B in 4T1 mam-
mary carcinoma cells reduced collagen degradation in
vitro, as assessed by our live-cell proteolysis assay, and
bone metastasis in vivo. Here using this live-cell proteoly-
sis assay, we observed differences in the degradation of
type IV collagen by the two IBC cell lines. These
Figure 6 Inhibition of cathepsin B activity attenuates invasiveness of SUM149 cells. SUM149 cells were subjected to transwell invasion
assays in the presence of DMSO (vehicle control) or 10 μM CA074. (a) Images are SUM149 cells that have invaded through rBM-coated filters;
bar, 150 μm. (b) Quantification of invaded cells was performed by counting the average number of nuclei from 10 fields of view per filter (using
Metamorph software) and expressed as percent control. Results from three independent experiments are presented as mean ± standard
deviation; *, P < 0.05.
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Page 10 of 14differences were further supported by variations in
expression and secretion of proteases and known caveo-
lae-associated proteins. We propose that these differ-
ences may be due, in part, to the differences in receptor
status of the two IBC cell lines. Although both lack estro-
gen and progesterone receptors, only SUM149 is HER2
negative, classifying it as a triple-negative breast cancer
cell line. Triple-negative breast cancer is a subtype of
breast cancer characterized as extremely aggressive, hav-
ing a poor prognosis and difficult to treat with high risks
of both recurrence and death [44,45]. A role for cathepsin
B has previously been reported in several triple-negative
breast cancer cell lines that are not IBC (e.g., BT20,
BT549, MCF-10AneoT, and MDA-MB-231) [31,46-48],
and inhibition of active cathepsin B in these cells reduced
their invasion in vitro. In vivo studies also provide evi-
dence for an association between cathepsin B and breast
cancers that are triple negative [49] (N Withana, BF
Sloane and BS Parker, unpublished observations). In
addition, a transgenic mouse model of mammary cancer
characterized by loss of hormone receptors with progres-
sion of disease [50] exhibited both reduced primary
tumor growth and lung metastases when deficient in
cathepsin B [51], suggesting a link between cathepsin B
expression and/or activity and invasive and metastatic
breast disease. This may be especially true in IBC as
expression of cathepsin B was found to be positively cor-
related with lymph node metastasis in IBC tissues, a cor-
relation not observed in non-IBC tissues [7]. As such,
cathepsin B has been proposed to be a prognostic marker
for IBC and potentially a component of a proposed mole-
cular signature for IBC that already includes caveolin-1
[16]. Our current findings show that cathepsin B and
caveolin-1 were co-expressed in tumor cells of IBC
patient samples and not in those of non-IBC patients.
Ongoing work will demonstrate if this co-expression is
elevated in triple-negative breast cancer patients other
than those diagnosed with IBC.
Another enzyme implicated in the aggressive IBC phe-
notype is RhoC GTPase, which is increased in expression
and activity [52,53]. We speculate that there may be a
network that links cathepsin B, caveolin-1, and Rho sig-
naling pathways in IBC. In colon, prostate, and non-IBC
tumors, phosphorylated caveolin-1 has been shown to
Figure 7 Immunohistochemical staining for cathepsin B and caveolin-1 in paraffin sections of inflammatory breast cancer tissues. (a)
Diffuse cytoplasmic staining for cathepsin B in tumor and stromal cells (magnification, 40×). (b) Cathepsin B staining in tumor emboli
(magnification, 40×). (c) Caveolin-1 staining in tumor emboli (arrow) and dermal lymphatic endothelial cells (arrowhead) (magnification: left
panel, 10×; right panel, 40×).
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Page 11 of 14promote migration and invasion via a Rho signaling path-
way [54]; this has not yet been assessed in IBC. A P132L
mutation in caveolin-1 confers a dominant-negative
effect on invasiveness of human schirrhous breast can-
cers [55] and upregulates genes involved in invasiveness
and metastasis, including Rho-related signaling molecules
and genes expressed by stem cells [56]. Studies in MDA-
MB-231 breast carcinoma cells by Bourguignon and col-
leagues [57] connect Rho, caveolin-1, and cathepsin B.
Rho kinase signaling events, mediated upstream by
CD44-NHE1 interactions localized to lipid microdomains
containing caveolin-1, result in acidification of the micro-
environment surrounding breast cancer cells, activate
secretion of cathepsin B and promote cellular invasive-
ness. We have previously shown that slight acidification
of the microenvironment of a variety of tumors (mela-
noma, colon, and breast) increases secretion and activity
of cathepsin B and proteolysis of type IV collagen
[8,58,59]. Whether there is a universal link between Rho,
caveolin-1, cathepsin B, and acidification of the tumor
microenvironment has not yet been evaluated.
Conclusions
Our in vitro data demonstrate that the cysteine protease
cathepsin B participates in degradation of type IV col-
lagen and invasion by IBC cells, likely through its associa-
tion with proteolytic pathways in caveolae at the cell
surface. These in vitro results are supported by the highly
significant co-expression of cathepsin B and caveolin-1 in
IBC cells of patient samples. Our study is the first to
show that cathepsin B, in association with caveolin-1,
contributes to the aggressive phenotype of IBC. This is
significant as both cathepsin B and caveolin-1 are poten-
tial biomarkers for the disease. Therefore, clinical
approaches targeting active cathepsin B may prove effica-
cious in the treatment of patients with IBC. Combina-
tional therapeutic approaches targeting both cathepsin B
and uPAR have been shown by Rao and colleagues to
inhibit tumor progression [60] and neovascularization in
malignant glioma [61]. Several protease targeted drugs
are routinely used in the clinic, for example, ACE inhibi-
tors, and others are in pre-clinical development, includ-
ing neutralizing antibodies against both cathepsin B and
uPA for cancer treatment (for review, see [62]).
Additional material
Additional file 1: supplementary movie 1. Degradation of DQ-
collagen IV by SUM149 cells grown in 3D rBM overlay culture.D Q -
collagen IV cleavage products (green) were imaged, and superimposed
on DIC images. Z-stack images captured by confocal microscopy were
used to generate 3D reconstructions.
Additional file 2: supplementary movie 2. Degradation of DQ-
collagen IV by SUM190 cells grown in 3D rBM overlay culture.D Q -
collagen IV cleavage products (green) were imaged, and superimposed
on DIC images. Z-stack images captured by confocal microscopy were
used to generate 3D reconstructions.
Additional file 3: supplementary movie 3. Degradation of DQ-
collagen IV by SUM149 cells grown in 3D rBM overlay culture
incubated with dimethyl sulfoxide (vehicle control). DQ-collagen IV
cleavage products (green) and nuclei, stained with DAPI (blue), were
imaged. Z-stack images captured by confocal microscopy were used to
generate 3D reconstructions.
Additional file 4: supplementary movie 4. Degradation of DQ
collagen IV by SUM149 cells grown in 3D rBM overlay culture
incubated with 10 μM CA074. DQ-collagen IV cleavage products
(green) and nuclei, stained with DAPI (blue), were imaged. Z-stack
images captured by confocal microscopy were used to generate 3D
reconstructions.
Additional file 5: supplementary table 1. Co-expression of caveolin-
1 and cathepsin B in carcinoma cells of IBC versus non-IBC tissues.
Immunohistochemical scores of 0 and + were considered negative and
scores of ++ and +++ were considered positive. Data presented as
number of patients (%). Chi-square = 11.3 (degrees of freedom = 1). IBC,
inflammatory breast cancer.
Abbreviations
2D: two-dimensional; 3D: three-dimensional; DMSO: dimethyl sulfoxide; ECM:
extracellular matrix; HRP: horseradish peroxidase; IBC: inflammatory breast
cancer; IHC: immunohistochemical; MMP: matrix metalloproteinase; PBS:
phosphate-buffered saline; pro-uPA: pro-urokinase-type plasminogen
activator; rBM: reconstituted basement membrane; SD: standard deviation; TI:
Triton X-100-insoluble; TS: Triton X-100-soluble; uPAR: urokinase receptor.
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